Hematologist and Medical Oncologist
Dr. Sameer Shrirangwar
Dr. Sameer Shrirangwar is a Consultant Medical Oncologist at the National Cancer Institute, Nagpur.
Dr. Sameer Shrirangwar
An experienced medical oncologist in Nagpur, with advanced training from premier national and international institutions, holds a DM in Medical Oncology from Tata Memorial Hospital, Mumbai, an MD in General Medicine from LTMMC, Sion, and an MBBS from Government Medical College, Nagpur. International credentials include MRCP (UK) in Medical Oncology from the Royal College of Physicians of Edinburgh, ESMO membership, and a Master’s degree in Molecular Oncology from the European School of Oncology, highlighting strong expertise in precision-driven and evidence-based cancer care.
The professional journey includes comprehensive oncology training and a specialist senior resident teaching role at Tata Memorial Hospital, along with earlier postgraduate residency in General Medicine at LTMMC, Mumbai. Actively involved in academic research and peer review, contributions extend to reputed oncology journals such as CRST, IJMPO, and SAJC. The clinical approach emphasizes patient-centered care, multidisciplinary coordination, and adherence to global oncology standards.
- Medical and Hemato Oncologist
- Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel Versus Docetaxel as second line or above therapy in re-current head and neck cancer. Oral Oncology75(2017)54–60 Amit Joshi, Vijay Patil, Kumar Prabhash, Sameer Shrirangwar
- Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus Docetaxel in recurrent head and neck cancer. CRST January-June 2018, 1(1):46-50 (DOI:10.4103/CRST.CRST_7_18) Amit Joshi, Vijay Patil, Kumar Prabhash, Sameer Shrirangwar
- Low prevalence of deficient Mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. J Gastrointest On-col2019 Feb;10(1):19-29 Anant Ramaswamy, Vikas Ostwal, Sameer Shrirangwar
- Adjuvant chemotherapy protocols for lung cancer in accordance with ASCO antiemetics and ASCO safety guidelines. CRST January-June 2018,1(1):19-40(DOI:10.4103/CRST.CRST_8_18) Sameer Shrirangwar, Manasi Sharma, Sunny Jandyal, Shruti Kate
- Kidney cancer demographics and outcome data from 2013 a tatertiary cancer hospital in India. Indian Journal of Cancer [01 Oct 2017, 54(4):601-604] Amit Joshi, Kumar Prabhash, Sameer Shrirangwar
- Prevalence of associated co-morbidities influencing choice of migraine prophylaxis in a Headache clinic. Journal of the association of physicians of India.Vol.67, January2019. Uma Sunder, Sameer Shrirangwar
- A randomized phase III trial comparing Nimotuzumab with Cisplatin chemoradiotherapy versus Cisplatin chemoradiotherapy alone in locally advanced head and neck cancer. Cancer Journal (ArticleID:CNCR32179,Ar-ticleDOI:10.1002/cncr.32179) Kumar Prabhash, Amit Joshi, Vijay Patil, Vanita Noronha, Sameer Shrirangwar
- Retrospective audit of using Abiraterone acetate in patients of metastatic castrate resistant prostate cancer (mCRPC). South Asian J Cancer2020; 9:23-6. Amit Joshi, Sameer Shrirangwar, Kumar Prabhash
- Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas are outcomes different in intestinal and pan-creatobiliary subtypes with adjuvant gemcitabine. HPB Journal (DOI:https://doi.org/10.1016/j.hpb.2019.07.006). Anant Ramaswamy, Vikas Ostwal, Sameer Shrirangwar
- Aspiration Pneumonia in head and neck cancer patients undergoing con-current chemoradiation from India-findings from a post hoc analysis of a Phase3study. CancerMed.2021;00:111 (DOI:https://doi.org/10.1002/cam4.4210) Vijay Patil, Kumar Prabhash, Sameer Shrirangwar
- Toxicity and tolerance of concurrent Docetaxel with radiotherapy in cisplatinin eligible head and neck cancer patients. JClinOncol36,2018 (suppl;abstre18022) Vijay Simha, Vijay Patil, Amit Joshi, Vanita Noronha ,Sameer Shrirangwar
- Treatment practices in gastrointestinal (GI) neuroendocrine carcinoma(NEC) Accepted as an abstract in GIESMO 2018
- Measurable Residual Disease In Acute Lymphoblastic Leukemia Treated With Non- Mrd Based Protocol Accepted as an abstract in ASPHO April 2021 (Pediatric blood and cancer journal)(https://doi.org/10.1002/pbc.29060) Pankaj Dwivedi, Kishor Deshpande, Sameer Shrirangwar
- Phase 3 randomized study for evaluation of physician choice Rx and Triple metronomic as second-line therapy in head and neck cancer (CRSF2021-HN-001) Rushabh Kothari, Vijay Patil, Anand Pathak, Sameer Shrirangwar
- Treatment pattern and outcomes of leptomeningeal carcinomatosis in India-a retrospective study. The Lancet Regional Health-Southeast Asia 2023,100331(https://doi.org/10.1016/j.lansea.2023.100331) Gautam Goyal, Ashish Singh, Manuprasad Avaronnan, Nirmal Vivek Raut, Vikas Talreja, Sameer Shrirangwar
- Author of chapter on Gatrointestinal stromal tumours written in TATA memorial centre, textbook of oncology, (Springer)
- Author of chapter on Renal cancer written in TATA memorial centre, textbook of oncology, (Springer)
- Author of chapter on Testicular cancer written in TATA memorial centre, textbook of oncology, (Springer)